Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States.
Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States.
Transplant Proc. 2021 Jan-Feb;53(1):353-357. doi: 10.1016/j.transproceed.2020.04.1819. Epub 2020 Jul 7.
Temporary mechanical circulatory support (MCS) devices are generally used short term to maintain adequate organ perfusion in patients with advanced heart failure and cardiogenic shock. Unacceptably high waitlist mortality in this cohort motivated changes to heart allocation policy, which recognized the severity of illness by prioritization for temporary MCS and broader sharing in the new U.S. donor heart allocation policy. We evaluated the post-heart transplant outcomes for patients bridged with temporary MCS, a control population not bridged with MCS, and a cohort bridged with durable MCS.
The heart transplant research database was queried to identify patients bridged with temporary MCS and bridged with durable MCS who went directly to heart transplant in our center. Temporary MCS included Impella, intra-aortic balloon pump, and extracorporeal membrane oxygenation. Post-transplant endpoints were assessed at 30 days, 6 months, and 1 year.
From 2010 to 2017, a total of 23 patients were bridged to heart transplant with temporary MCS and 548 were transplanted without MCS bridge. Patients bridged with temporary MCS had younger age, lower body mass index, and higher frequencies of prior blood transfusion and Status 1 (1A/1B) listing at transplant compared to patients not bridged with MCS (all P < .001). Despite the severity of illness in patients bridged with temporary MCS, post-transplant outcomes were indistinguishable from those in patients transplanted without MCS bridge, with no difference in 30-day, 6-month, or 1-year survival or 1-year freedom from cardiac allograft vasculopathy, nonfatal major adverse cardiac events, any-treated rejection, acute cellular rejection, or antibody-mediated rejection (P = .23-.97). Similarly, compared to 157 patients bridged with durable MCS, no differences in post-transplant outcomes were identified for the temporary MCS cohort (P = .15-.94).
Temporary MCS as a bridge to transplant achieves similar post-transplant outcomes at 1 year compared to no MCS and durable MCS. These encouraging findings support recent changes in the Organ Procurement and Transplantation Network | United Network Organ Sharing (OPTN|UNOS) adult heart allocation policy.
临时机械循环支持(MCS)装置通常用于在晚期心力衰竭和心源性休克患者中维持足够的器官灌注。该队列的候补名单死亡率过高,促使心脏分配政策发生变化,该政策通过临时 MCS 的优先级排序和新的美国供心分配政策的更广泛共享来认识到疾病的严重程度。我们评估了使用临时 MCS 桥接的患者、未使用 MCS 桥接的对照组患者和使用耐用 MCS 桥接的患者的心脏移植后结局。
心脏移植研究数据库被查询,以确定在我们中心直接进行心脏移植的使用临时 MCS 桥接的患者和使用耐用 MCS 桥接的患者。临时 MCS 包括 Impella、主动脉内球囊泵和体外膜氧合。移植后终点在 30 天、6 个月和 1 年进行评估。
2010 年至 2017 年,共有 23 例患者使用临时 MCS 桥接至心脏移植,548 例患者未使用 MCS 桥接。与未使用 MCS 桥接的患者相比,使用临时 MCS 桥接的患者年龄更小、体重指数更低、输血和移植时状态 1(1A/1B)列表的频率更高(均 P <.001)。尽管使用临时 MCS 桥接的患者病情严重,但移植后的结果与未使用 MCS 桥接的患者无差异,30 天、6 个月或 1 年生存率或 1 年免于心脏同种异体移植物血管病、非致命性主要不良心脏事件、任何治疗的排斥反应、急性细胞排斥反应或抗体介导的排斥反应无差异(P =.23-.97)。同样,与使用耐用 MCS 桥接的 157 例患者相比,临时 MCS 队列的移植后结果无差异(P =.15-.94)。
与不使用 MCS 和耐用 MCS 相比,临时 MCS 作为移植桥接在 1 年内获得相似的移植后结局。这些令人鼓舞的发现支持了器官获取和移植网络|美国器官共享网络(OPTN|UNOS)成人心脏分配政策的最新变化。